Precision Medicine

A new partnership between Hong Kong's PAIR and the UK's Cambridge NeuroWorks aims to accelerate brain health innovations through a global seminar series.

Glucotrack seeks FDA trial approval for its revolutionary 3-year implantable glucose monitor, racing against financial clocks to change diabetes care.

A key workshop aims to bridge the gap between FDA policy and patient needs, seeking to streamline therapy development for millions with rare diseases.

A new partnership uses AI to eliminate costly subjectivity in brain disorder research, promising to accelerate new treatments and improve data integrity.

The biopharma posts record Q1 revenue and profit, driven by its flagship DefenCath and a key acquisition, while a promising pipeline signals future growth.

Dr. Amie Hornaman's bestseller, The Thyroid Fix, confronts medical gaslighting, empowering women to look beyond 'normal' lab results for answers.

Early human trial data for a new drug, UDP-003, suggests it can safely remove toxic cholesterol, a key step toward reversing arterial plaque buildup.

On May 18, competitors like Ulta and CVS join forces for National Sun Responsibly Day, an urgent call to make daily sun protection a life-saving habit.

With strong HIFU revenue and new clinical trials, EDAP TMS's upcoming Investor Day will reveal its strategy for medtech dominance and investor confidence.

A new partnership integrates Factor's ready-to-eat meals with Berry Street's insured dietitian network, using your meal data to offer personalized advice.

A new partnership aims to solve the massive underdiagnosis of a severe genetic disorder by offering free testing, a move with deep strategic implications.

The Virginia-based startup landed a major funding round to automate liquid biopsy sample prep, aiming to make cancer detection faster and more reliable.

A $25M payment from partner Chiesi catapults Protalix to a profitable quarter, funding a promising new gout therapy and a broader rare disease strategy.

With a new CEO, a half-billion-dollar war chest, and a novel drug pipeline, Damora Therapeutics is making an aggressive play to redefine blood cancer treatment.

A Belgian firm's new biologic gel for diabetic foot ulcers gets a key FDA green light, offering hope against a leading cause of amputations.

A new specialty clinic in Philadelphia tackles a nationwide shortage of pet dentists, offering advanced, team-based oral care for common animal ailments.

Autoimmune diagnostics firm Exagen reports a 12% revenue jump and improved efficiency, fueling analyst optimism and setting a strong tone for 2026.

Anaveon reveals promising ASCO data for its cancer drug ANV600, yet puts the asset on the market to fund a bold new focus on autoimmune diseases.

OncLive® unveils its 2026 class of inductees, 14 visionaries whose groundbreaking work is transforming the future of oncology and bringing hope to millions.

An innovative RNA-editing therapy for hepatocellular carcinoma has received a major FDA designation, potentially accelerating its path to patients.